<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Allogeneic hematopoietic SCT (HSCT) is currently the only curative treatment for <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>However, many patients cannot find an HLA-matched donor </plain></SENT>
<SENT sid="2" pm="."><plain>We have developed a new protocol for HLA-mismatched (including haploidentical) HSCT using G-CSF-primed BM plus G-CSF-mobilized PBSCs without in vitro T-cell <z:mpath ids='MPATH_63'>depletion</z:mpath> </plain></SENT>
<SENT sid="3" pm="."><plain>A total of 36 patients diagnosed with high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> (<z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts) or RAEBt (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in transformation)) underwent transplantation from HLA-mismatched family donors </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients achieved sustained myeloid engraftment </plain></SENT>
<SENT sid="5" pm="."><plain>The cumulative incidence of grades II-IV <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD (aGVHD) was 60% and that of grades III and IV aGVHD was 15% </plain></SENT>
<SENT sid="6" pm="."><plain>The 2-year cumulative incidence of <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD was 56% </plain></SENT>
<SENT sid="7" pm="."><plain>After a median follow-up of 17 months, 4 patients had relapsed and died and 25 patients were still alive </plain></SENT>
<SENT sid="8" pm="."><plain>The 2-year probability of <z:hpo ids='HP_0001909'>leukemia</z:hpo>-free survival (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LFS</z:e>) was 65% </plain></SENT>
<SENT sid="9" pm="."><plain>Patients transplanted within 7 months of diagnosis had better <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LFS</z:e> (89 vs 43% ) </plain></SENT>
<SENT sid="10" pm="."><plain>Severe aGVHD decreased the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LFS</z:e> significantly by increasing non-relapse mortality (NRM) </plain></SENT>
<SENT sid="11" pm="."><plain>This study confirms that HLA-mismatched HSCT is a treatment option for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>Patients with high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> benefit from receiving HSCT early in the course of the disease </plain></SENT>
</text></document>